34 results about "Sustained-Release Preparations" patented technology

The invention relates to the technical field of pharmaceutical preparations, in particular to a solid dispersion-based sustained-release drug composite carrier as well as a preparation method and application thereof. The preparation method comprises the following steps: carrying out synergistic spray drying on double polymers (hydroxypropyl methylcellulose acetate succinate and polyvinylpyrrolidone-vinyl acetate copolymer) to form a solid dispersion; compounding with mesoporous silica and calcium silicate for localization, and spraying ethanol to activate pores; calcium stearate and magnesium stearate are sequentially added for lubrication; prefabricating a sustained-release skeleton master batch; and finally, mixing, rolling and forming. According to the method, through hierarchical structural design, the drug stability, the powder fluidity and the release controllability are remarkably improved, the method is suitable for industrial production of the dihydroergoline mesylate sustained release preparation, and a release curve is smooth and reliable.

The application discloses a sustained-release preparation of indobufen and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The application relates to a sustained-release preparation of indobufen and a preparation method and application thereof. The preparation has the characteristics of stable sustained-release effect, high bioavailability, good drug-taking compliance and small side effect, and is suitable for the prevention and / or treatment of diseases such as ischemic cardiovascular diseases, ischemic cerebrovascular diseases and venous thrombosis.

The invention provides a sitagliptin and metformin sustained-release pharmaceutical composition as well as a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer, the sustained-release tablet core comprises an active ingredient metformin hydrochloride and a sustained-release framework material hydroxypropyl methylcellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises an active component sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methylcellulose in the sustained release tablet core is 50: (24-27). The composition utilizes a double-layer structure to realize double-phase release of the medicine; the microcrystalline cellulose is removed, and the specific ratio of the active component to the framework material is limited, so that the moldability and ideal dissolution behavior of the preparation are ensured while the tablet weight is remarkably reduced to improve the swallowing compliance, and the technical problem that the slow-release framework function is difficult to maintain under the condition that the weight of a high-drug-loading-capacity compound preparation is greatly reduced is successfully solved.

The application provides a sitagliptin and metformin hydrochloride sustained-release pharmaceutical composition and a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer; the sustained-release tablet core comprises active ingredients metformin hydrochloride and a sustained-release matrix material hydroxypropyl methyl cellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises active ingredients sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methyl cellulose in the sustained-release tablet core is 50:(24-27). The composition realizes double-phase release of drugs by using a double-layer structure; by removing the microcrystalline cellulose and limiting the specific ratio of active ingredients to the matrix material, the forming property of the preparation and the ideal dissolution behavior are ensured while the tablet weight is significantly reduced to improve the swallowing compliance, and the technical problem that a high drug loading compound preparation is difficult to maintain the function of the sustained-release matrix under a large amount of weight reduction is successfully solved.

The present application relates to microspheres having a physiologically active substance uniformly dispersed therein and sustained-release preparations containing the same. In the present application, microspheres are provided, which are microspheres having a physiologically active substance uniformly dispersed therein with a lactic acid / glycolic acid copolymer (PLGA) as a main component, characterized in that the average volume-based particle diameter of the microspheres is 1 μm or more and 150 μm or less, and no lump or pore of the physiologically active substance of 1.5 μm or more is present in the microspheres. The microspheres of the present application can appropriately control the initial release amount of the physiologically active substance and the release rate during the period thereafter, and continuously release the physiologically active substance in vivo for a certain period.

The invention discloses a cat and dog gastrointestinal inflammation alleviator containing plant extracts and application of the cat and dog gastrointestinal inflammation alleviator, and relates to the field of pet health. The alleviator is prepared by compounding a plant extract component, a micro-ecological component, a functional auxiliary component and a carrier raw material, plant active components are purified by adopting an ultrasonic-assisted ethanol gradient elution combined membrane separation technology, and the problem of antagonism of a plant extract and probiotics is solved through microcapsule embedding and step-by-step compounding. The sustained-release preparation is prepared by combining sustained-release preparation forming and palatability optimization technologies. The traditional Chinese medicine composition can synergistically achieve the effects of resisting inflammation, repairing gastrointestinal mucosa, regulating intestinal flora and quickly stopping diarrhea, is suitable for preventing and treating acute and chronic enterogastritis of cats and dogs, and is good in palatability, high in stability, free of obvious toxic and side effects and convenient to administrate.

The invention discloses a preparation method of a traditional Chinese medicine composition for treating skin tinea, allergic dermatitis and acne, and relates to the field of pharmaceutical preparations, the extraction rate of gallic acid and ethyl gallate contained in total tannin in fructus chebulae flesh, fructus terminaliae billericae flesh and fructus chebulae immaturus is improved through an enzymolysis method, and the transfer rate of effective components of quercetin is improved through a boiling granulation technology; therefore, the effect of treating psoriasis of the composition is improved. By adopting a boiling granulation technology, the technical problems of long preparation period and high cost in the prior art are solved. The release speed of aloe in intestinal tracts is controlled by adopting a slow release technology, and the upper and lower limit content range of barbaloin is controlled to reduce the occurrence rate of adverse reactions of the composition. Meanwhile, butyl hydroxy anisd (BHA), butylated hydroxytoluene (BHT) and a citric acid system are adopted, so that the problems of PEO skeleton degradation, out-of-control drug release behavior and insufficient main drug stability of the barbaloin-PEO sustained release preparation are solved.

The application belongs to the technical field of microbial preparation, and specifically discloses a kind of SA-MPN encapsulated bacteriophage preparation and its preparation method and application, its preparation method includes the following steps: take bacteriophage cocktail concentrate, add tannic acid solution, FeCl3·6H2O solution, phosphate buffer solution, obtain metal phenolic aldehyde network encapsulated bacteriophage;Subsequently, CaCl2 solution and sodium alginate solution are added to the metal phenolic aldehyde network encapsulated bacteriophage in sequence, to obtain sodium alginate-metal phenolic aldehyde network-bacteriophage mixture microcapsules.The application adopts the above-mentioned SA-MPN encapsulated bacteriophage preparation and its preparation method and application, which can effectively protect bacteriophage from gastric acid, high temperature and ultraviolet stress, realize intestinal targeting and slow release, has high encapsulation efficiency, good stability, antioxidant activity, significant antibacterial effect on salmonella and high biological safety.

The invention discloses a sustained release preparation based on composite carrier coated calcium peroxide, a preparation method and application, and belongs to the technical field of aquaculture substrate improvement, and the preparation method comprises the following steps: S1, adding a layered silicate clay mineral into water, heating and stirring, then adding an organosilane modifier for reaction, standing at constant temperature for a certain time, and filtering to obtain a filter cake; filtering to obtain activated layered silicate clay minerals; s2, pouring the activated layered silicate clay mineral obtained in the step S1 into a mixed aqueous solution of sodium alginate and food-grade white granulated sugar, stirring to obtain an activated montmorillonite-sodium alginate composite carrier solution, then adding calcium peroxide, and performing secondary stirring for a certain time to obtain a calcium peroxide-carrier mixed solution; and then introducing into an injector, dripping into normal-temperature deionized water to prepare small balls with a certain size, freezing, and drying in stages to obtain the sustained release preparation based on calcium peroxide wrapped by the composite carrier. The calcium peroxide loading capacity can be improved, and the calcium peroxide release period can be prolonged.

The invention provides a long-acting injection preparation based on an alpha-lipoic acid derivative and a preparation method and application thereof, and the preparation method of the long-acting injection preparation comprises the following steps: taking alpha-lipoic acid as a carboxylic acid donor and n-hexylamine as a primary amine donor, and carrying out reaction in a system of EDC and NHS to generate N-hexyl lipoic amide; n-hexyl lipoic amide and alpha-lipoic acid are dissolved in dimethyl sulfoxide according to the mass ratio of 1: 1 for a reaction, and the long-acting injection preparation is obtained. The long-acting injection preparation can realize in-situ phase change and drug long-acting slow release through solvent diffusion response, has good injectability and biocompatibility, can be used as a drug delivery carrier, and is used for long-term treatment of chronic metabolic diseases.

The invention relates to the technical field of data processing, and discloses a walnut disease grading prevention and control method and system and a storage medium. The method comprises the steps of collecting multi-band spectrum and temperature data of walnut trees to calculate disease characteristic indexes, constructing an orchard network according to inter-tree positions and propagation relations, inputting a graph convolutional network to extract time-space correlation information and output a disease grading result, and performing region division based on the grading result to determine differentiated medicament schemes. And preparing an environmental response type sustained release preparation, and carrying out targeted drug delivery according to a zoning scheme. The problems that in the prior art, disease diagnosis efficiency is low, grading subjectivity is high, and a space-time propagation rule cannot be captured are solved.

The present application provides a resin composition comprising at least a resin (A) which is a copolymer of ethylene and a vinyl monomer containing an oxygen atom, a carboxylic acid ester (B) having a linear or branched chain with a vapor pressure of 1.0 x 10 －4 Pa or more at 25°C, and an insect repellent (C) having a vapor pressure of 1.0 x 10 －4 Pa or more at 25°C, wherein the amount of the resin (A) is 10 to 87 mass%, the amount of the carboxylic acid ester (B) is 3 to 30 mass%, the amount of the insect repellent (C) is 10 to 60 mass%, and the mass ratio of the carboxylic acid ester (B) to the insect repellent (C) is 2:1 to 1:5, based on the total amount of the resin composition.

The invention belongs to the technical field of pharmacy, and particularly relates to a rhizoma phragmitis sustained release preparation for hyperuricemia and a preparation method of the rhizoma phragmitis sustained release preparation. The reed rhizome sustained release preparation for hyperuricemia is prepared from the following raw materials in parts by weight: 80 to 100 parts of reed rhizome extract, 160 to 200 parts of functionalized reed rhizome powder, 0.01 to 0.1 part of freeze-dried powder, 40 to 65 parts of quercetin and 30 to 50 parts of acrylic resin, the rhizoma phragmitis extract and quercetin cooperate to comprehensively regulate uric acid metabolism; due to the introduction of the freeze-dried powder, real-time visual monitoring of in-vivo drug distribution and drug release progress is realized, and the targeting affinity of the preparation with intestinal mucosa and joint parts can be improved, so that the blood uric acid level quickly tends to be stable and is maintained for a long time; after the colon target positioning sustained-release pellet and the quercetin quick-release pellet are mixed, the quick-release pellet can be quickly disintegrated and release quercetin to realize quick acid control, and the sustained-release pellet can accurately deliver drugs in the colon and continuously release active ingredients to realize long-acting acid stabilization.

The application discloses an oral preparation capable of improving 5-HT level in the brain and application thereof in improving insomnia, and belongs to the field of food science. The oral preparation uses starch and beta-cyclodextrin as nanoparticle carriers to wrap 5-HTP, can effectively control the release rate of 5-HTP, makes it slowly release in the gastrointestinal tract, and improves the defect that the half-life of 5-HTP is short. The preparation can significantly improve the content of 5-HT in the brain, and improve the metabolic kinetic characteristics of 5-HT, thereby effectively improving the insomnia symptoms. Experimental data shows that, compared with the traditional 5-HTP, the slow-release preparation has better bioavailability and longer brain drug efficacy duration. The innovative preparation not only has significant advantages in technology, but also opens up a new, safe and effective way for the treatment of 5-HT related nervous system diseases, and has important application value and research significance.

The invention discloses application of cimicifugin in preparation of a medicine for preventing or treating inner ear hair cell injury, and belongs to the technical field of biological medicine. According to the invention, it is found for the first time that a natural compound cimifugin has a definite inner ear hair cell protection effect. By inhibiting hair cell apoptosis and reducing hearing synapse loss and hearing nerve fiber injury, the cimicifugin effectively relieves hair cell injury and hearing function decline caused by cis-platinum and other drugs, noise exposure and aging. The protection mechanism is related to inhibition of activation of a pro-apoptosis signal. The preferred administration mode is local administration, especially delivery through a round window membrane, and the dosage form can be a solution, a suspension or a sustained release preparation. Cell, in-vitro hair cell tissue and animal model experiments prove that the cimicifugin can obviously relieve hair cell damage and improve the auditory function. The invention provides a new drug candidate scheme for preventing and treating sensorineural hearing loss, and has important clinical application value.

The invention belongs to the field of biological pharmacy, and particularly discloses application of evodiamine in inhibition of migration and invasion of gallbladder cancer cells and metastatic tumor growth. Aiming at the problems of poor drug targeting, high toxicity, easy drug resistance and the like in gallbladder cancer hepatic metastasis treatment, the invention provides various application forms of evodiamine: 1) an evodiamine single-drug sustained release preparation (PLGA or chitosan carrier) realizes long-acting sustained release through local intervention or intratumor injection; 2) the evodiamine liposome preparation (the ratio of DPPC to cholesterol is 3: 1, and the particle size is 80-150nm) can improve the enrichment rate of hepatic metastatic focus to 5.8% or above; (3) the evodiamine and chemotherapeutic drugs (oxaliplatin, 5-FU and the like) are combined to form a composition, and the synergy index is Cilt; 0.8, the toxicity of the system is obviously reduced; animal experiments show that the liver metastasis inhibition rate reaches 82.7% and the weight loss rate is only 10.5% when the liposome (3 mg / kg of evodiamine and 6 mg / kg of oxaliplatin) is combined, and a high-efficiency and low-toxicity solution is provided for gallbladder carcinoma metastasis.

The present application provides a kind of tofacitinib citrate sustained-release preparation, which is composed of tablet core, sustained-release layer coating and color layer coating, and the sustained-release layer coating has drug release small holes. By adjusting the composition of osmotic pressure forming agent and its dosage ratio with sustained-release agent, further optimizing the composition and coating weight of sustained-release layer coating, not only the defect of slow dissolution rate after long-term storage when using sorbitol as osmotic pressure forming agent alone is avoided, but also the initial release rate of tofacitinib citrate sustained-release tablet is improved, and slow and sustained release can be maintained for 6 hours, the drug release is more complete, the blood drug concentration is kept at a uniform and stable level for a long time, the fluctuation of blood drug concentration during the interval of administration is reduced, the bioavailability is further improved, the adverse reactions are reduced, and the clinical efficacy and safety are protected.

The application belongs to the field of pharmaceutical chemistry, and particularly relates to a glucocorticoid prodrug, a preparation method and application thereof. The glucocorticoid prodrug has low solubility, is suitable for preparation of a long-acting sustained-release preparation, and compared with existing dexamethasone palmitate preparations on the market, the compound of the application provides more excellent long-acting sustained-release effect, while effectively reducing systemic drug exposure, thereby minimizing or avoiding systemic side effects possibly caused by glucocorticoids.

The application provides a sustained-release preparation of beta-hydroxybutyric acid or a salt thereof, which comprises the following components by weight percentage: 40-50% of beta-hydroxybutyric acid or a salt thereof, 40-60% of a sustained-release skeleton matrix material, and 1-3% of an auxiliary material. The product of the application has excellent water dispersion performance, and can realize slow release of beta-hydroxybutyric acid or a salt, maintain stable and effective blood drug concentration for a long time in the body, and has very important significance for the practical application of beta-hydroxybutyric acid and a salt.

The invention discloses a compound antibacterial sustained release preparation for gestational diabetes mellitus combined infection and a preparation method thereof, and relates to the technical field of medicines.The preparation method comprises the following steps that S1, a PLGA-PEG-esterase substrate copolymer, nisin and dipotassium glycyrrhizinate are jointly dissolved in an organic solvent through a nanoprecipitation method, and an organic phase is formed; injecting the organic phase into a water phase containing polyvinylpyrrolidone accounting for 0.5%-2% of the weight of the water phase at the shear rate of 5000-10000 rpm, and mixing; according to the compound antibacterial sustained-release preparation for gestational diabetes mellitus complicated with infection and the preparation method thereof, the poloxamer 407 / chitosan temperature-sensitive gel matrix enables the preparation to be a liquid which is easy to perfuse at room temperature, is convenient for administration, and is rapidly converted into a semi-solid gel at body temperature after entering the vagina, so that the residence time of the preparation in the vagina is prolonged, and long-acting sustained release is realized.

The invention provides a melogabalin besylate sustained release preparation. The melogabalin besylate sustained release preparation is prepared from the following components: melogabalin besylate, polyoxyethylene, polyvinylpolypyrrolidone, sodium alginate and microcrystalline cellulose, the mass ratio of the melogabalin besylate to the polyoxyethylene to the polyvinylpolypyrrolidone to the sodium alginate to the microcrystalline cellulose is (0.5-8): (20-40): (5-15): (20-40): (6-35). The sustained release preparation can ensure that melogabalin besylate is continuously released and absorbed in vivo, so that the drug effect is improved, the adverse reaction is reduced and the treatment effect is enhanced while the administration frequency is reduced.

The invention discloses a preparation method and application of an ethyl cellulose standard substance based on GPC preparative chromatography. The method aims at an ethyl cellulose sample with the ethyoxyl content of 48.0%-49.5% and the number-average molecular weight of 15000-40000 g / mol, and comprises the following steps: preparing a'tetrahydrofuran + N, N-dimethylformamide / dimethyl sulfoxide 'mixed solvent, and dissolving the sample at room temperature to form a 0.5%-2% clear solution; the method comprises the following steps: by taking ethyl cellulose as a raw material, adopting two styrene-divinyl benzene copolymer filler GPC (Gel Permeation Chromatography) chromatographic columns which are connected in series, taking a mixed solvent as a mobile phase, monitoring and separating through a differential refraction detector, and collecting to obtain a target chain segment product (Mn = 20000-23000 g / mol and PDI < = 2.3), namely the exclusive standard substance of ethyl cellulose. When the prepared ethyl cellulose standard substance is used for molecular weight calibration, the deviation is reduced from 15%-22% to less than or equal to 2.5%. The method realizes deep coupling of separation purification-quality calibration, has the advantages of strong adaptability, high separation precision, high efficiency, accurate calibration and the like, is suitable for quality control in the fields of medical sustained release preparations, high-end coatings and the like, and is suitable for industrial production.

The invention discloses a preparation method of a cinobufagin / ganoderan nanoparticle composite sustained-release preparation, and relates to a composite sustained-release preparation as well as a preparation method and application thereof. The invention aims to solve the problems of high toxicity and the like caused by short in-vivo half-life period and wide whole-body distribution of cinobufagin in anti-tumor application. According to the cinobufagin / ganoderan nanoparticle composite sustained-release preparation disclosed by the invention, due to introduction of gel coating, the cinobufagin / ganoderan nanoparticle composite sustained-release preparation has a more lasting sustained-release property, the treatment effect of cinobufagin can be played for a long time, toxic and side effects are reduced, the cinobufagin is prevented from being cleared by multiple organs, most of medicines act on target organs, and a very good treatment effect is achieved. The good anti-tumor effect is realized; meanwhile, the damage to organs is reduced.

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a preparation method and application of a bone marrow focus targeting traditional Chinese medicine sustained release preparation. The traditional Chinese medicine sustained release preparation for targeting the bone marrow focus comprises the following raw materials in parts by mass: 15-25 parts of oldenlandia diffusa, 5-15 parts of sculellaria barbata, 20-30 parts of astragalus membranaceus, 10-20 parts of dandelion, 5-12 parts of herba violae, 5-15 parts of gynura bicolor, 1-3 parts of sodium alginate, 1-3 parts of hyperbranched polylysine, 1-2 parts of poloxamer, 1-5 parts of a polylactic acid-glycolic acid copolymer and 5-15 parts of a calcium chloride solution. And 5-10 parts of polyvinyl alcohol. The sustained and controllable release of the traditional Chinese medicine components in the osteomyelitis focus part is realized, the long-acting anti-infection and bone repair promoting potential is achieved, and the preparation method is simple and suitable for large-scale popularization and application.

The invention discloses a trazodone sustained-release tablet and a preparation method thereof, and belongs to the field of pharmaceutical preparations, and the sustained-release tablet contains trazodone hydrochloride, a sustained-release framework material, a pore-foaming agent, an adhesive and other pharmaceutic adjuvants. The preparation method comprises the following steps: preparing sustained-release particles from trazodone hydrochloride, a skeleton sustained-release material and other necessary auxiliary materials by adopting a hot-melt extrusion granulation process, and then mixing and tabletting the sustained-release particles and the auxiliary materials to prepare the trazodone sustained-release tablet. The preparation process is simple, the production reproducibility is relatively good, the sustained release effect of the product is good, the release behavior of the product is relatively consistent with that of a foreign original sustained release preparation, and the problems that the original product is easy to break and high in friability are solved.

The application belongs to the tobacco mildew prevention technical field, and particularly relates to application of essential oil slow-release beads in preparation of cigar leaf and cigarette mildew-proof products. The application provides application of essential oil slow-release beads in preparation of cigar leaf and cigarette mildew-proof products, wherein the essential oil slow-release beads comprise a bacteriostatic active substance and a slow-release carrier, the bacteriostatic component is continuously and slowly released through the coating effect of the slow-release carrier, thereby achieving a convenient mildew-proof method which does not need to be sprayed and can be directly placed with finished cigar cigarettes, the method does not affect the quality of cigars, can prolong the duration of the mildew-proof effect, and avoids the problem of short-term effect caused by one-time release; meanwhile, the mildew-proof slow-release preparation has a broad-spectrum bacteriostatic effect, can effectively inhibit the growth of various molds such as Aspergillus corntus, Aureobasidium pullulans and Scopulariopsis, and is suitable for long-term mildew-proof protection of the fermentation process of cigar leaves and the aging process of finished cigars.

The invention provides a pharmaceutical composition containing melogabalin besylate as an active ingredient. The pharmaceutical composition comprises the following components: melogabalin besylate, polyoxyethylene, polyvinylpolypyrrolidone, sodium alginate and mannitol, the mass ratio of the melogabalin benzene sulfonate to the polyoxyethylene to the polyvinylpolypyrrolidone to the sodium alginate to the mannitol is (0.5-8): (20-40): (5-15): (20-40): (3-20). The pharmaceutical composition is a sustained release preparation, and can ensure that melogabalin besylate is continuously released and absorbed in vivo, so that the drug effect is improved, the adverse reaction is reduced, and the treatment effect is enhanced while the administration frequency is reduced.

The invention belongs to the technical field of pharmaceutical compositions, and relates to an alkaloid long-acting analgesic injection in-situ gel and a preparation method and application thereof, the alkaloid long-acting analgesic injection in-situ gel comprises the following components by weight: 0.2-10 parts of an alkaloid analgesic drug, 50-90 parts of an organic solvent, and 10-50 parts of a drug carrier; the drug carrier is formed by polymerizing one or more of lactic acid, glycolic acid, ethylene glycol or ethylene oxide monomers. According to the alkaloid long-acting analgesic injection in-situ gel disclosed by the invention, the alkaloid analgesic drug is combined with the drug carrier with good biocompatibility and biodegradability, the alkaloid analgesic drug is successfully prepared into a sustained release preparation, and the alkaloid long-acting analgesic injection in-situ gel has a slow release capability, can obviously reduce the administration frequency, effectively improves the product quality and has a good application prospect. The problems of poor addiction and biocompatibility of analgesic drugs which are widely used clinically at present are solved.